NASDAQ:ANTH - Anthera Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.0855 -0.01 (-10.47 %) (As of 07/15/2018 03:26 PM ET)Previous Close$0.0855Today's Range$0.0852 - $0.099052-Week Range$0.07 - $2.97Volume107,026 shsAverage Volume1.89 million shsMarket Capitalization$2.07 millionP/E Ratio-0.02Dividend YieldN/ABeta2.72 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California. Receive ANTH News and Ratings via Email Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ANTH CUSIPN/A Webwww.anthera.com Phone510-856-5600 Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Price-To-Earnings Trailing P/E Ratio-0.02 Forward P/E Ratio-0.04 P/E GrowthN/A Sales & Book Value Annual Sales$140,000.00 Price / Sales15.99 Cash FlowN/A Price / CashN/A Book Value($0.42) per share Price / Book-0.20 Profitability EPS (Most Recent Fiscal Year)($3.75) Net Income$-26,870,000.00 Net MarginsN/A Return on Equity-3,347.91% Return on Assets-366.62% Miscellaneous Employees21 Outstanding Shares26,180,000Market Cap$2.07 Anthera Pharmaceuticals (NASDAQ:ANTH) Frequently Asked Questions What is Anthera Pharmaceuticals' stock symbol? Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH." When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work? Anthera Pharmaceuticals shares reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split. How were Anthera Pharmaceuticals' earnings last quarter? Anthera Pharmaceuticals Inc (NASDAQ:ANTH) posted its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Zacks' consensus estimate of ($0.82) by $0.09. View Anthera Pharmaceuticals' Earnings History. When is Anthera Pharmaceuticals' next earnings date? Anthera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Anthera Pharmaceuticals. What price target have analysts set for ANTH? 4 equities research analysts have issued 1 year price targets for Anthera Pharmaceuticals' shares. Their predictions range from $0.50 to $10.00. On average, they expect Anthera Pharmaceuticals' stock price to reach $4.50 in the next year. This suggests a possible upside of 5,163.2% from the stock's current price. View Analyst Ratings for Anthera Pharmaceuticals. What is the consensus analysts' recommendation for Anthera Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anthera Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Are investors shorting Anthera Pharmaceuticals? Anthera Pharmaceuticals saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 2,015,026 shares, an increase of 52.5% from the May 31st total of 1,320,966 shares. Based on an average trading volume of 1,232,840 shares, the days-to-cover ratio is presently 1.6 days. Approximately 7.8% of the shares of the stock are short sold. View Anthera Pharmaceuticals' Current Options Chain. Who are some of Anthera Pharmaceuticals' key competitors? Some companies that are related to Anthera Pharmaceuticals include Immune Therapeutics (IMUN), Amarillo Biosciences (AMAR), Immune Pharmaceuticals (IMNP), Acura Pharmaceuticals (ACUR), Marina Biotech (MRNA), Biostar Pharmaceuticals (BSPM), Boston Therapeutics (BTHE), Stellar Biotechnologies (SBOT), Bioblast Pharma (ORPN), Cotinga Pharmaceuticals (COTQF), Orexigen Therapeutics (OREX), Praxsyn (PXYN), GlobeImmune (GBIM), Aoxing Pharmaceutical (AOXG) and Respirerx Pharmaceuticals (RSPI). Who are Anthera Pharmaceuticals' key executives? Anthera Pharmaceuticals' management team includes the folowing people: Mr. Paul F. Truex, Exec. Chairman (Age 49)Mr. John Craig Thompson, Pres, CEO & Director (Age 51)Dr. Renee Martin Ph.D., Sr. VP of Medical Sciences (Age 49)Dr. William R. Shanahan Jr., M.D., J.D., Chief Medical Officer & Sr. VP (Age 69)Ms. May Liu, Chief Accounting Officer, Sr. VP of Fin. & Admin. and Compliance Officer (Age 42) Has Anthera Pharmaceuticals been receiving favorable news coverage? News coverage about ANTH stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anthera Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.76 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. How do I buy shares of Anthera Pharmaceuticals? Shares of ANTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Anthera Pharmaceuticals' stock price today? One share of ANTH stock can currently be purchased for approximately $0.0855. How big of a company is Anthera Pharmaceuticals? Anthera Pharmaceuticals has a market capitalization of $2.07 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-26,870,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. Anthera Pharmaceuticals employs 21 workers across the globe. How can I contact Anthera Pharmaceuticals? Anthera Pharmaceuticals' mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company can be reached via phone at 510-856-5600. MarketBeat Community Rating for Anthera Pharmaceuticals (NASDAQ ANTH)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 253 (Vote Outperform)Underperform Votes: 239 (Vote Underperform)Total Votes: 492MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What does EPS mean?